Billal Tedbirt

Billal Tedbirt

Auto-generated profile, based on publicly available information

Billal Tedbirt

Department of Dermatology and INSERM U 1234, Centre de référence des maladies bulleuses auto-immunes, Normandie University, Rouen University Hospital , Rouen

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 April 2021 in JAMA Dermatology
Verified
Journal Article
Open access
PDF file
BTBillal Tedbirt
Billal Tedbirt
AGAndré Gillibert
André Gillibert
EAEmilie Andrieu
Emilie Andrieu
VHVivien Hébert
Vivien Hébert
SBSarah Bastos
Sarah Bastos
PJPascal Joly
Pascal Joly
Bullous pemphigoid (BP) is the most common autoimmune subepidermal blistering disease of the skin, which mainly affects elderly patients with frequent neurological comorbidities.1 Bullous pemphigoid is associated with significant morbidity and an increased death rate that seems to differ throughout the world. In Europe, the 1-year death rate ranged from 0 to 52%,2,3 whereas it ranged from 11% to 23% in the US4,5 and from 0 to 42% in Asia.6,7

1 May 2019 in European Journal of Cancer
Verified
Journal Article
Closed access
BTBillal Tedbirt
Billal Tedbirt
MPMichel De Pontville
Michel De Pontville
PBPierre Branger
Pierre Branger
CPCamille Picard
Camille Picard
BBBarouyr Baroudjian
Barouyr Baroudjian
JDJulie Delyon
Julie Delyon

1 April 2025 in JAMA Dermatology
Verified
Journal Article
Closed access
BTBillal Tedbirt
Billal Tedbirt
EHEstelle Houivet
Estelle Houivet
MMMaud Maho-Vaillant
Maud Maho-Vaillant
MGMarie-Laure Golinski
Marie-Laure Golinski
SCSébastien Calbo
Sébastien Calbo
PJPascal Joly
Pascal Joly
This cohort study examines the safety and efficacy of rituximab for patients with pempigus foliaceus.

4 November 2022 in Dermatology
Verified
Journal Article
Closed access
PDF file
AWAnne Welfringer-Morin
Anne Welfringer-Morin
MBMarion Barroil
Marion Barroil
SFSylvie Fraitag
Sylvie Fraitag
VSVanessa Szablewski
Vanessa Szablewski
OBOlivia Boccara
Olivia Boccara
BCBodemer Christine
Bodemer Christine
Background: Our objective was to describe the clinical, histological characteristics, and disease outcome of a cohort of mycosis fungoides (MF) diagnosed during childhood including disease status at adulthood. Methods: This is a retrospective multicentre survey of patients aged under 18 years at diagnosis with histologically confirmed MF. Patients’ clinical and histological characteristics, treatments, and disease outcome (for patients followed for more than 12 months) were analysed. Results: Forty-six patients were included (median age at diagnosis: 11 years; M:F sex ratio: 3:1) with 39 (85%) followed for at least 12 months. Thirty-nine patients (85%) had stage I MF. Hypopigmented patches were observed in 48% and folliculotropism in 43% patients. Immunophenotype of the skin infiltrate was predominantly CD8+ in 17% of patients. Initial management included a wait-and-see strategy in 6/39 (15%), skin-directed treatment in 27 (69%), and systemic treatment in 6 (15%) patients, respectively, with partial or complete clinical response (PR or CR) observed in 28 patients (72%). 14/39 patients (36%) relapsed after initial response. After a median follow-up period of 54 months, disease status at last news was PR or CR in 31/39 (79%), stable disease in 6 (15%), and progression in 2 (5%) patients. Histological transformation was observed in 3/39 (8%). Of the 15 patients followed until adulthood, 13 (87%) had persistent MF. Discussion: This survey confirms the high frequency of hypopigmented and folliculotropic lesions and of CD8+ immunophenotype compared to adult MF patients. The long-term course is usually indolent but transformation may occur sometimes long after disease onset and the disease may persist during adulthood.

31 December 2020 in Contact Dermatitis
Verified
Journal Article
Closed access
PDF file
BTBillal Tedbirt
Billal Tedbirt
MVMarie‐Hortense Viart‐Commin
Marie‐Hortense Viart‐Commin
PCPriscille Carvalho
Priscille Carvalho
PCPhilippe Courville
Philippe Courville
FTFlorence Tétart
Florence Tétart

12 April 2022 in JID Innovations
Verified
Journal Article
Open access
MGMarine Guignant
Marine Guignant
BTBillal Tedbirt
Billal Tedbirt
Dedee MurrellDedee Murrell
Dedee Murrell
MAMasayuki Amagai
Masayuki Amagai
Valeria AokiValeria Aoki
Valeria Aoki
PJPascal Joly
Pascal Joly
Many treatments are currently proposed for treating patients with bullous pemphigoid (BP). We assessed treatment modalities of BP depending on the different countries, BP extent, and patients’ comorbidities. We surveyed worldwide experts about how they treat patients with BP. A total of 61 experts from 27 countries completed the survey. Severe and moderate BP were treated with oral prednisone (61.4 and 53.7%, respectively) or superpotent topical corticosteroids (CSs) (38.6 and 46.3%, respectively). Conventional immunosuppressants were more frequently combined with oral prednisone (74.5%) than with superpotent topical CS (37.5%) in severe BP. Topical CSs were mainly used in Europe in mild (81.1%), moderate (55.3%), and severe (54.3%) BP. In the United States of America and Asia, systemic CSs were mainly proposed for treating severe (77.8 and 100%, respectively), moderate (70 and 77.8%, respectively), and also mild (47.1 and 33.3%, respectively) BP. Most experts reduced the initial dose of oral CS in patients with diabetes mellitus (48.1%) or cardiac insufficiency (40.2%) but rarely changed BP treatment in patients with neurological disorders or neoplasia. This survey showed major differences in the way patients with BP are treated between AmeriPac countries (United State of America, Latin America, and Australia) and Asia on the one hand and Europe and the Middle East on the other hand.